Trials / Completed
CompletedNCT04257032
A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
Relative Bioavailability of Rosuvastatin (Part 1) and Dabigatran (Part 2) Given Alone and Together With BI 1323495 in Healthy Male Subjects (Open, Single-dose, Randomised, Two-period Crossover Design in Each Trial Part)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate the relative bioavailabilities of rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and together with BI 1323495 (Test 1, Test 2) following oral administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin | Tablet |
| DRUG | Rosuvastatin + BI 1323495 | Tablets |
| DRUG | Dabigatran etexilate | Capsule |
| DRUG | Dabigatran etexilate + BI 1323495 | Capsule and tablets |
Timeline
- Start date
- 2020-02-13
- Primary completion
- 2020-09-23
- Completion
- 2020-09-23
- First posted
- 2020-02-05
- Last updated
- 2024-02-23
- Results posted
- 2024-02-23
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04257032. Inclusion in this directory is not an endorsement.